NASDAQ:MDWD - Mediwound Stock Price, Forecast & News

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

Mediwound Ltd (NASDAQ:MDWD) issued its quarterly earnings data on Thursday, November, 14th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.12. The biopharmaceutical company had revenue of $5.14 million for the quarter, compared to analyst estimates of $2.67 million. Mediwound had a negative return on equity of 94.57% and a net margin of 69.50%. View Mediwound's Earnings History.

Mediwound is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Mediwound.

2 equities research analysts have issued twelve-month target prices for Mediwound's stock. Their forecasts range from $5.50 to $7.00. On average, they anticipate Mediwound's stock price to reach $6.25 in the next year. This suggests a possible upside of 118.5% from the stock's current price. View Analyst Price Targets for Mediwound.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mediwound.

News coverage about MDWD stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mediwound earned a news impact score of 0.7 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Mediwound.

Mediwound saw a drop in short interest during the month of November. As of November 15th, there was short interest totalling 147,700 shares, a drop of 23.3% from the October 31st total of 192,600 shares. Based on an average daily volume of 37,600 shares, the short-interest ratio is presently 3.9 days. Approximately 1.0% of the company's shares are short sold. View Mediwound's Current Options Chain.

Some companies that are related to Mediwound include Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), True Drinks (TRUU), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE) and Beleave (BE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Blackstone Group (BX), Mastercard (MA), Wells Fargo & Co (WFC), Braskem (BRKMY), Caesarstone (CSTE), Chubb (CB), Nordic American Tanker (NAT), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

Mediwound's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.78%), Oppenheimer & Co. Inc. (0.18%) and Sargent Investment Group LLC (0.17%).

MDWD stock was purchased by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, California Public Employees Retirement System and Oppenheimer & Co. Inc..

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MDWD stock can currently be purchased for approximately $2.86.

Mediwound has a market capitalization of $77.73 million and generates $3.40 million in revenue each year. The biopharmaceutical company earns $-1,060,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Mediwound employs 73 workers across the globe.View Additional Information About Mediwound.

The official website for Mediwound is http://www.mediwound.com/.

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]